Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company’s Phase 3 antifungal, and CB-012, its Cloudbreak® antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American Society for Microbiology (ASM) Microbe 2019 annual meeting taking place June 20-24 in San Francisco.
June 5, 2019
· 8 min read